NOT KNOWN DETAILS ABOUT BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until finally condition progression or maybe the participants are not able to tolerate the study drugs.- Participant eaten grapefruit or grapefruit solutions within 3 times previous to the p